Protokinetix, Inc. (QB) Stock Price - PKTX

Best deals to access real time data!
Small Cap Pro
Monthly Subscription
for only
Canna Trader Pro
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Protokinetix, Inc. (QB) PKTX Other OTC Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  -0.0067 -3.35% 0.1932 0.23 0.18 0.18 0.1999 11:43:15
Bid Price Ask Price Spread Spread % News
0.189 0.217 0.028 12.90% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
16 87,775 $ 0.206812 $ 18,153 206,830 0.05 - 0.32
Last Trade Time Type Quantity Stock Price Currency
11:43:15 2,100 $ 0.1932 USD

Protokinetix, Inc. (QB) Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 52.71M 272.80M $ -1.22M - - 161.81M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
20.20k $ - 0.00% - -

more financials information »

Protokinetix, Inc. (QB) News

Loading Messages....

Latest PKTX Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical PKTX Price Data

Period † Open High Low VWAP Avg. Daily Vol [m] Change %
1 Week0.20020.230.180.193646k-0.007-3.50%
1 Month0.21510.237450.1620.204465k-0.0219-10.18%
3 Months0.140.320.130.2241214k0.053238.00%
6 Months0.07470.320.050.1723184k0.1185158.63%
1 Year0.07610.320.050.1572121k0.1171153.88%
3 Years0.0480.320.030.1060118k0.1452302.50%
5 Years0.030.320.0120.0923112k0.1632544.00%

Protokinetix, Inc. (QB) Description

ProtoKinetix is a molecular biotechnology company that has developed and patented a family of hyper stable, potent glycopeptides (AAGP) that enhance both engraftment and protection of transplanted cells used in regenerative medicine. Due to the results achieved over the last four years of testing, the University of Alberta has begun Phase 1 human clinical trials. Additional studies will be expanded to include whole organ transplantation and all therapies that are being developed globally to date; diabetes, retinal degeneration, cardiac repair and many other degenerative conditions. In addition, we are studying the potential impact on several cancer therapies.

Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.